12:00 AM
Jun 03, 2013
 |  BC Week In Review  |  Company News  |  Other News

Atopix Therapeutics, Medical Research Council, U.K. Technology Strategy Board (TSB) dermatology news

In April, Atopix received a £1.7 million ($2.6 million) award from the U.K. Biomedical Catalyst fund to develop the company's lead compound, OC459, to treat moderate-to-severe atopic dermatitis. The product...

Read the full 140 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >